CA2710862C - Pharmaceutical composition for treating diabetes and preparation method thereof - Google Patents
Pharmaceutical composition for treating diabetes and preparation method thereof Download PDFInfo
- Publication number
- CA2710862C CA2710862C CA2710862A CA2710862A CA2710862C CA 2710862 C CA2710862 C CA 2710862C CA 2710862 A CA2710862 A CA 2710862A CA 2710862 A CA2710862 A CA 2710862A CA 2710862 C CA2710862 C CA 2710862C
- Authority
- CA
- Canada
- Prior art keywords
- solution
- volumetric flask
- pharmaceutical composition
- tube
- taking
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 72
- 238000002360 preparation method Methods 0.000 title claims abstract description 40
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 35
- 210000004369 blood Anatomy 0.000 claims abstract description 81
- 239000008280 blood Substances 0.000 claims abstract description 81
- 238000003908 quality control method Methods 0.000 claims abstract description 12
- 239000000243 solution Substances 0.000 claims description 173
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 105
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 95
- 238000012360 testing method Methods 0.000 claims description 90
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 78
- 239000008103 glucose Substances 0.000 claims description 78
- 238000010438 heat treatment Methods 0.000 claims description 69
- 239000006228 supernatant Substances 0.000 claims description 64
- 239000013558 reference substance Substances 0.000 claims description 47
- 239000012488 sample solution Substances 0.000 claims description 44
- 238000005406 washing Methods 0.000 claims description 42
- 238000001816 cooling Methods 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 31
- 239000008055 phosphate buffer solution Substances 0.000 claims description 31
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 28
- 230000000694 effects Effects 0.000 claims description 25
- 210000002966 serum Anatomy 0.000 claims description 25
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 23
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 22
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 21
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 claims description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 20
- 239000006187 pill Substances 0.000 claims description 20
- 238000005303 weighing Methods 0.000 claims description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 19
- 239000000706 filtrate Substances 0.000 claims description 19
- 238000010992 reflux Methods 0.000 claims description 19
- 239000000741 silica gel Substances 0.000 claims description 19
- 229910002027 silica gel Inorganic materials 0.000 claims description 19
- 239000002671 adjuvant Substances 0.000 claims description 18
- 238000004809 thin layer chromatography Methods 0.000 claims description 15
- LOTKRQAVGJMPNV-UHFFFAOYSA-N 1-fluoro-2,4-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C([N+]([O-])=O)=C1 LOTKRQAVGJMPNV-UHFFFAOYSA-N 0.000 claims description 14
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 14
- 235000012907 honey Nutrition 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 14
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 14
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 14
- 239000003826 tablet Substances 0.000 claims description 14
- 239000002775 capsule Substances 0.000 claims description 13
- 238000001514 detection method Methods 0.000 claims description 13
- 238000012856 packing Methods 0.000 claims description 13
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 12
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 claims description 12
- 238000009835 boiling Methods 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 12
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 12
- 238000002791 soaking Methods 0.000 claims description 12
- 239000000600 sorbitol Substances 0.000 claims description 12
- 229940109239 creatinine Drugs 0.000 claims description 11
- 239000003405 delayed action preparation Substances 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 11
- IXZISFNWUWKBOM-ARQDHWQXSA-N fructosamine Chemical compound NC[C@@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O IXZISFNWUWKBOM-ARQDHWQXSA-N 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 11
- 239000007924 injection Substances 0.000 claims description 11
- 210000003734 kidney Anatomy 0.000 claims description 11
- 239000012141 concentrate Substances 0.000 claims description 10
- 238000005507 spraying Methods 0.000 claims description 10
- 210000003743 erythrocyte Anatomy 0.000 claims description 8
- 210000003497 sciatic nerve Anatomy 0.000 claims description 8
- 238000001704 evaporation Methods 0.000 claims description 7
- 239000001632 sodium acetate Substances 0.000 claims description 7
- 229920002527 Glycogen Polymers 0.000 claims description 6
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
- 230000001684 chronic effect Effects 0.000 claims description 6
- 229940096919 glycogen Drugs 0.000 claims description 6
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims description 6
- 229960004949 glycyrrhizic acid Drugs 0.000 claims description 6
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims description 6
- 239000001685 glycyrrhizic acid Substances 0.000 claims description 6
- 235000019410 glycyrrhizin Nutrition 0.000 claims description 6
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 6
- 230000014759 maintenance of location Effects 0.000 claims description 6
- 239000007901 soft capsule Substances 0.000 claims description 6
- 239000006196 drop Substances 0.000 claims description 5
- 206010020710 Hyperphagia Diseases 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 230000008021 deposition Effects 0.000 claims description 4
- 206010036067 polydipsia Diseases 0.000 claims description 4
- 208000022530 polyphagia Diseases 0.000 claims description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 4
- 210000004926 tubular epithelial cell Anatomy 0.000 claims description 4
- 201000001119 neuropathy Diseases 0.000 claims description 3
- 230000007823 neuropathy Effects 0.000 claims description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 239000000463 material Substances 0.000 claims 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 6
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims 2
- 239000005695 Ammonium acetate Substances 0.000 claims 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 2
- 229940043376 ammonium acetate Drugs 0.000 claims 2
- 235000019257 ammonium acetate Nutrition 0.000 claims 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims 2
- 235000017281 sodium acetate Nutrition 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 238000009210 therapy by ultrasound Methods 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 abstract description 6
- 206010016766 flatulence Diseases 0.000 abstract description 3
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 70
- 241000700159 Rattus Species 0.000 description 60
- 230000003345 hyperglycaemic effect Effects 0.000 description 51
- 241000699670 Mus sp. Species 0.000 description 31
- 239000005720 sucrose Substances 0.000 description 23
- 229940079593 drug Drugs 0.000 description 19
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 18
- 229960002632 acarbose Drugs 0.000 description 18
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 18
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 17
- 229930006000 Sucrose Natural products 0.000 description 17
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 17
- 230000008569 process Effects 0.000 description 17
- 229920002472 Starch Polymers 0.000 description 14
- 239000008107 starch Substances 0.000 description 14
- 235000019698 starch Nutrition 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 9
- 239000013641 positive control Substances 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 9
- 238000003304 gavage Methods 0.000 description 8
- 229960003180 glutathione Drugs 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 235000008429 bread Nutrition 0.000 description 7
- 239000004382 Amylase Substances 0.000 description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 6
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 6
- UKKNXSQVJWQTAV-UHFFFAOYSA-N [Na].C(=O)N(C)C.C(C)#N Chemical compound [Na].C(=O)N(C)C.C(C)#N UKKNXSQVJWQTAV-UHFFFAOYSA-N 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 238000007670 refining Methods 0.000 description 5
- 229950005143 sitosterol Drugs 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- ALSPKRWQCLSJLV-UHFFFAOYSA-N azanium;acetic acid;acetate Chemical compound [NH4+].CC(O)=O.CC([O-])=O ALSPKRWQCLSJLV-UHFFFAOYSA-N 0.000 description 4
- 210000000695 crystalline len Anatomy 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 210000005239 tubule Anatomy 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 3
- 239000004367 Lipase Substances 0.000 description 3
- 108090001060 Lipase Proteins 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000000738 kidney tubule Anatomy 0.000 description 3
- 229940040461 lipase Drugs 0.000 description 3
- 235000019421 lipase Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 3
- 229960001243 orlistat Drugs 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 2
- 102000043296 Lipoprotein lipases Human genes 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 102000019280 Pancreatic lipases Human genes 0.000 description 2
- 108050006759 Pancreatic lipases Proteins 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 2
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 201000008627 kidney hypertrophy Diseases 0.000 description 2
- 235000019626 lipase activity Nutrition 0.000 description 2
- 206010062198 microangiopathy Diseases 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 229940116369 pancreatic lipase Drugs 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 229910021487 silica fume Inorganic materials 0.000 description 2
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 2
- 229940117972 triolein Drugs 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 102000002268 Hexosaminidases Human genes 0.000 description 1
- 108010000540 Hexosaminidases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- 102400000472 Sucrase Human genes 0.000 description 1
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 1
- 102000016679 alpha-Glucosidases Human genes 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Insects & Arthropods (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100571303A CN101496829B (zh) | 2008-01-30 | 2008-01-30 | 一种治疗消渴病的药物组合物及其制备方法 |
| CN200810057130.3 | 2008-01-30 | ||
| PCT/CN2008/001878 WO2009100605A1 (zh) | 2008-01-30 | 2008-11-14 | 一种治疗消渴病的药物组合物及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2710862A1 CA2710862A1 (en) | 2009-08-20 |
| CA2710862C true CA2710862C (en) | 2019-02-26 |
Family
ID=40944238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2710862A Active CA2710862C (en) | 2008-01-30 | 2008-11-14 | Pharmaceutical composition for treating diabetes and preparation method thereof |
Country Status (4)
| Country | Link |
|---|---|
| CN (1) | CN101496829B (zh) |
| CA (1) | CA2710862C (zh) |
| GB (1) | GB2469220B (zh) |
| WO (1) | WO2009100605A1 (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104095178A (zh) * | 2013-04-09 | 2014-10-15 | 北京宏泰康达医药科技有限公司 | 一种辅助降血糖的组合物 |
| CN103536649B (zh) * | 2013-10-17 | 2015-05-20 | 漳州片仔癀药业股份有限公司 | 一种金糖宁胶囊的制备方法 |
| CN104007206B (zh) * | 2014-06-13 | 2015-05-27 | 漳州片仔癀药业股份有限公司 | 一种蚕沙药材的检测方法 |
| CN104007205B (zh) * | 2014-06-13 | 2015-09-30 | 漳州片仔癀药业股份有限公司 | 一种治疗消渴病的药物制剂的检测方法 |
| CN105004829B (zh) * | 2015-07-21 | 2017-06-16 | 漳州片仔癀药业股份有限公司 | 一种金糖宁胶囊的质量检测方法 |
| CN109007145A (zh) * | 2018-07-26 | 2018-12-18 | 佛山科学技术学院 | 一种多效保健红茶饮料的制备方法 |
| CN110279719B (zh) * | 2019-06-27 | 2021-01-15 | 北京市房山区中医医院 | 治疗糖尿病胃轻瘫的晚蚕沙外熨包及其制备和使用方法 |
| CN114594178B (zh) * | 2022-01-25 | 2024-04-02 | 贵州健安德科技有限公司 | 一种利用hplc检测30%氯虫苯甲酰胺悬浮剂中3-甲基吡啶的方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5908628A (en) * | 1998-05-01 | 1999-06-01 | Hou; Liping | Compositions with analgesic, antipyretic and antiinflammatory properties |
| CN1152692C (zh) * | 1999-06-14 | 2004-06-09 | 中国医学科学院药物研究所 | 蚕沙提取方法、提取物及其用途 |
| US6350476B1 (en) * | 2000-05-22 | 2002-02-26 | Shanxi Zhengzhon Pharmaceutical Co., Ltd. | Herbal chinese joint complex |
| KR20030079237A (ko) * | 2002-04-02 | 2003-10-10 | 최진호 | 누에 추출물을 이용한 항당뇨환자식의 조성물 |
| US20070160687A1 (en) * | 2004-02-06 | 2007-07-12 | Kim Jin S | Composition for prevention and treatment of diabetic complication |
| CN1557824A (zh) * | 2004-02-13 | 2004-12-29 | 南开大学 | 蚕沙总生物碱及其制备方法 |
| CN1250246C (zh) * | 2004-02-23 | 2006-04-12 | 南开大学 | 具有α－糖苷酶抑制活性的药物组合物及其用途 |
| CN100425268C (zh) * | 2005-11-15 | 2008-10-15 | 李乃荣 | 一种治疗痛风的药物 |
| CN100372544C (zh) * | 2005-12-09 | 2008-03-05 | 南开大学 | 一种蚕沙总生物碱及其制备方法 |
-
2008
- 2008-01-30 CN CN2008100571303A patent/CN101496829B/zh active Active
- 2008-11-14 GB GB1009713.7A patent/GB2469220B/en active Active
- 2008-11-14 CA CA2710862A patent/CA2710862C/en active Active
- 2008-11-14 WO PCT/CN2008/001878 patent/WO2009100605A1/zh active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| GB2469220B (en) | 2012-10-24 |
| GB2469220A (en) | 2010-10-06 |
| GB201009713D0 (en) | 2010-07-21 |
| CA2710862A1 (en) | 2009-08-20 |
| CN101496829B (zh) | 2011-09-14 |
| WO2009100605A1 (zh) | 2009-08-20 |
| CN101496829A (zh) | 2009-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2710862C (en) | Pharmaceutical composition for treating diabetes and preparation method thereof | |
| Miura et al. | [Retracted] Management of Diabetes and Its Complications with Banaba (Lagerstroemia speciosa L.) and Corosolic Acid | |
| Deng et al. | Anti-hyperglycemic effects and mechanism of traditional Chinese medicine Huanglian Wan in streptozocin-induced diabetic rats | |
| Sharma et al. | attenuates streptozotocin induced diabetic cardiomyopathy via inhibition of oxidative stress and inflammatory response in rats | |
| CN110787230B (zh) | 一种治疗糖尿病及糖尿病肾病的中药提取物组合物及质量检测方法 | |
| US20230057861A1 (en) | Use of corydalis saxicola bunting and formulation thereof in preparation of drug for treating non-alcoholic fatty liver diseases | |
| CN101849950A (zh) | 救必应酸在制备调血脂的药物中的应用 | |
| CN111407783A (zh) | 赶黄草在制备治疗高蛋白尿药物中的应用 | |
| CN101015597A (zh) | 厚朴制剂在制备治疗糖尿病和肥胖症药物中的应用 | |
| CN104244937A (zh) | 含ramalin的用于预防或治疗肝纤维化和肝硬化的药物组合物 | |
| CN102309542A (zh) | 用于慢性肾炎的肾茶正丁醇部位药及其制备方法 | |
| CN101912446B (zh) | 连翘氯仿提取物在制备治疗糖尿病药物中的应用 | |
| CN1933846A (zh) | 含有黄褥花果叶萃取物的血糖水平升高抑制剂和age生成抑制剂以及含有它们的食品 | |
| CN102614247A (zh) | 小豆(菜豆、四棱豆)提取物在制备抗糖尿病药物中的应用 | |
| CN103664568B (zh) | 环草石斛二聚芪类化合物及其制备方法和应用 | |
| CN103432124B (zh) | 氧化苦参碱在制备防治糖尿病肾病药物中的应用 | |
| CN110314160A (zh) | 小檗胺在制备预防和治疗糖尿病肾病药物中的应用 | |
| CN112451558A (zh) | 牛大力醇提物在制备降糖或降脂药物、保健品中的应用 | |
| KR20030059951A (ko) | 소풍순기원 생약 복합제 추출물을 함유하는 당뇨병 예방및 치료를 위한 조성물 | |
| CN101249129B (zh) | 一种治疗糖尿病的中药提取物组合物及其医药用途 | |
| KR100473531B1 (ko) | 변방 소풍순기원 생약 복합제 추출물을 함유하는 당뇨병예방 및 치료를 위한 조성물 | |
| CN106608899B (zh) | 20(r)-原人参三醇及衍生物的制备方法和医药用途 | |
| CN115381901B (zh) | 石斛液体制剂的制药用途 | |
| CN116942723B (zh) | 一种具有保护肾功能健康的杜仲叶提取物及其制备、检测方法 | |
| CN101775026B (zh) | 螺环生物碱化合物及含其的药物组合物及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |